Halozyme Therapeutics Inc (HALO) - Total Assets
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) holds total assets worth $2.22 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Halozyme Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Halozyme Therapeutics Inc - Total Assets Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check HALO operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Halozyme Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Halozyme Therapeutics Inc's total assets of $2.22 Billion consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.6% |
| Accounts Receivable | $308.45 Million | 15.0% |
| Inventory | $141.86 Million | 6.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $401.83 Million | 19.5% |
| Goodwill | $416.82 Million | 20.2% |
Asset Composition Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HALO stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Halozyme Therapeutics Inc's current assets represent 52.6% of total assets in 2024, a decrease from 100.0% in 2001.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2024, down from 100.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 20.2% of total assets.
Halozyme Therapeutics Inc Competitors by Total Assets
Key competitors of Halozyme Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Halozyme Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 10.36 | 1.32 |
| Quick Ratio | 1.37 | 9.15 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $491.52 Million | $1.02 Billion | $133.38 Million |
Halozyme Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Halozyme Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.42 |
| Latest Market Cap to Assets Ratio | 4.06 |
| Asset Growth Rate (YoY) | 19.1% |
| Total Assets | $2.06 Billion |
| Market Capitalization | $8.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Halozyme Therapeutics Inc's assets at a significant premium (4.06x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Halozyme Therapeutics Inc's assets grew by 19.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual total assets of Halozyme Therapeutics Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.06 Billion | +19.05% |
| 2023-12-31 | $1.73 Billion | -5.88% |
| 2022-12-31 | $1.84 Billion | +66.74% |
| 2021-12-31 | $1.10 Billion | +90.44% |
| 2020-12-31 | $579.92 Million | +2.48% |
| 2019-12-31 | $565.87 Million | +28.54% |
| 2018-12-31 | $440.25 Million | -15.33% |
| 2017-12-31 | $519.95 Million | +98.82% |
| 2016-12-31 | $261.51 Million | +43.86% |
| 2015-12-31 | $181.79 Million | +9.53% |
| 2014-12-31 | $165.98 Million | +63.05% |
| 2013-12-31 | $101.79 Million | -24.45% |
| 2012-12-31 | $134.73 Million | +104.88% |
| 2011-12-31 | $65.76 Million | -28.01% |
| 2010-12-31 | $91.35 Million | +18.40% |
| 2009-12-31 | $77.15 Million | +0.77% |
| 2008-12-31 | $76.56 Million | -26.00% |
| 2007-12-31 | $103.46 Million | +124.47% |
| 2006-12-31 | $46.09 Million | +124.72% |
| 2005-12-31 | $20.51 Million | +25.03% |
| 2004-12-31 | $16.40 Million | +34421.69% |
| 2003-12-31 | $47.52K | -51.14% |
| 2002-12-31 | $97.25K | +272.22% |
| 2001-12-31 | $26.13K | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more